Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Regulatory perspective in safety and efficacy of new drug approval
- In: C4 - Paradigm shift in research and development on Tuesday, 6 September 2011, 14:00-17:00
- At: Hyderabad (India) (2011)
- Type: Presentation
- By: KAMBOJ, Rajender (Lupin Ltd., Pune, India)
New drug development process is becoming increasingly tougher. R&D timelines & costs are consistently rising. Adding to this challenge, drugs are getting withdrawn from the market & there is a growing expectation of all stakeholders from regulatory authorities to approve safer drugs. Like never before, the drug development and approval process.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019